Establishment Labs Announces Full Enrollment in Motiva US IDE Study

SANTA BARBARA, Calif.–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving the health and well-being of women, primarily in the area of ​​aesthetics and breast reconstruction, announced today that it has completed enrollment in the Motiva US IDE Clinical Study. The last surgery in the primary reconstruction cohort was performed at Northwestern Memorial Hospital. The Augmentation Cohort, which completed enrollment in August 2019, will complete its third year of study follow-up this month.

“Conducting such a rigorous FDA clinical trial during a global pandemic while maintaining a high level of patient follow-up is a testament to the dedication of the study surgeons, healthcare professionals, and facility labs,” said Dr. Caroline Glicksman, medical director of and researcher in the Motiva IDE study. “The entire investigation team can be proud of their efforts to provide women with access to new options in breast surgery.”

The Motiva US IDE study recruited 827 patients at 32 centers in the United States, Germany and Sweden. The study is designed to evaluate the safety and effectiveness of Motiva breast implants in primary breast augmentation, primary breast reconstruction and breast revision procedures. The study included 562 patients in the augmentation cohorts and 265 in the reconstruction cohorts. The study includes a magnetic resonance imaging (MRI) cohort of 250 patients who receive MRIs at years 1, 2, 3, 5, 7, and 10 to assess silent rupture.

“Having completed full enrollment in the IDE study in all patient groups, we are working diligently with the plastic surgeons in the trial to maintain high patient follow-up,” said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. “We are very pleased with our progress in the augmentation cohort, and expect to file our PMA submission with the FDA in the fourth quarter of this year for aesthetic indications.”

“Motiva implants have created a new standard in my practice for post-mastectomy reconstruction,” added Professor Dr. Phillip Blondeel, Professor of Plastic Surgery and Chairman of the Department of Plastic and Reconstructive Surgery at Ghent University Hospital, in Belgium ; President of the European Society of Plastic Surgery (EURAPS); and director of the Beautiful After Breast Cancer Foundation. “With Motiva, we can consistently achieve the aesthetic results that women hope for in their reconstruction, and in doing so, we are helping to turn breast cancer into a treatable disease that women can fully recover from.”

The pivotal Motiva Core study is an ongoing US clinical trial of an investigational medical device licensed by the FDA. Investigational Device Exemption. The Motiva device has not been approved by the Food and Drug Administration and is not commercially available in the United States.

About Institutional Laboratories

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving the health and well-being of women. The initial focus of the company is breast health, primarily aesthetics and breast reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded Motiva Implants®, that include a number of innovative, patented features designed to deliver better aesthetic and clinical outcomes. Since commercial launch in 2010, more than 2.0 million Motiva® implants have been delivered to plastic surgeons in more than 80 countries. The Company also offers or has in development a number of related products and technologies, including the Motiva Flora® tissue expander and Mía®, the Company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an Investigational Device Exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva® implants are manufactured at the company’s two factories in Costa Rica, which comply with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for more information at www.establishmentlabs.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). ). You can find many (but not all) of these statements by searching for words such as “approaches”, “believes”, “expects”, “anticipates”, “estimates”, “intends to “, “plans”, “intends”, “” “would”, “will”, “could” or other similar expressions in this press release. Any statement that refers to projections of our financial performance or future operating conditions, anticipated trends in our business, our objectives, strategies, priorities and plans, including the development and commercialization of related products and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to business performance are forward-looking statements.We claim the safe harbor protection contained in the Private Securities Litigation Reform Act of 1995. We remind investors that all forward-looking statements set forth in this report, or which we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on information currently available at the time such statements are made. . These statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors beyond our control. Although we believe our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. Therefore, our actual future results and timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in the forward-looking statements include risks and uncertainties relating to: our ability to develop, research and successfully obtain, timely and cost-effectively gain regulatory approval to and market our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to develop and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid significant disruption to our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; the effect on our business of the current conflict between Russia and Ukraine; the impact of foreign currency exchange rates; the impact on our business of an economic downturn or deterioration in general macroeconomic conditions, including slower growth or recession, inflation or decline in purchasing power or consumer confidence; other economic and competitive factors; and other risks and uncertainties discussed in Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K filed March 1, 2022 and on Form 10-Q for the three months ended March 31, 2022, filed on May 10, 2022. These and other factors that could cause or contribute to actual results differing materially from our expectations may also be changed, updated or replaced from time to time in other filings in the future. by the company with the Securities and Exchange Commission. The risks included in these materials are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a highly competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all of these risk factors, or to assess the impact of all of these risk factors on our business or the extent to which any one factor, or a combination of factors, may cause actual results to differ materially from those contained in the forward-looking statements. We assume no obligation to update forward-looking statements. Accordingly, investors should exercise caution when relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

Comments are closed.